

Marco Siccardi

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/4090422/marco-siccardi-publications-by-year.pdf>

Version: 2024-04-25

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

126
papers

2,816
citations

31
h-index

46
g-index

131
ext. papers

3,120
ext. citations

5
avg. IF

4.94
L-index

#	Paper	IF	Citations
126	PBPK Modelling of Dexamethasone in Patients With COVID-19 and Liver Disease.. <i>Frontiers in Pharmacology</i> , 2022 , 13, 814134	5.6	0
125	A physiologically based pharmacokinetic model to predict pegylated liposomal doxorubicin disposition in rats and human.. <i>Drug Delivery and Translational Research</i> , 2022 , 1	6.2	0
124	Physiologically based pharmacokinetic modeling for dose optimization of quinine-phenobarbital coadministration in patients with cerebral malaria. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2021 , 11, 104	4.5	1
123	Predicting Drug-Drug Interactions between Rifampicin and Ritonavir-Boosted Atazanavir Using PBPK Modelling. <i>Clinical Pharmacokinetics</i> , 2021 , 1	6.2	1
122	Recommendations for Dosing of Repurposed COVID-19 Medications in Patients with Renal and Hepatic Impairment. <i>Drugs in R and D</i> , 2021 , 21, 9-27	3.4	15
121	Effect of ageing on antiretroviral drug pharmacokinetics using clinical data combined with modelling and simulation. <i>British Journal of Clinical Pharmacology</i> , 2021 , 87, 458-470	3.8	7
120	Clinical Data Combined With Modeling and Simulation Indicate Unchanged Drug-Drug Interaction Magnitudes in the Elderly. <i>Clinical Pharmacology and Therapeutics</i> , 2021 , 109, 471-484	6.1	4
119	Long-acting drugs and formulations for the treatment and prevention of HIV infection. <i>International Journal of Antimicrobial Agents</i> , 2021 , 57, 106220	14.3	23
118	In Vitro assessment of the potential for dolutegravir to affect hepatic clearance of levonorgestrel. <i>HIV Medicine</i> , 2021 , 22, 898-906	2.7	
117	Predicting Pharmacokinetics of a Tenofovir Alafenamide Subcutaneous Implant Using Physiologically Based Pharmacokinetic Modelling. <i>Antimicrobial Agents and Chemotherapy</i> , 2020 , 64,	5.9	4
116	The challenging pathway towards the identification of SARS-CoV-2/COVID-19 therapeutics. <i>Journal of Antimicrobial Chemotherapy</i> , 2020 , 75, 2381-2383	5.1	1
115	Physiologically-Based Pharmacokinetic Modeling for Optimal Dosage Prediction of Quinine Coadministered With Ritonavir-Boosted Lopinavir. <i>Clinical Pharmacology and Therapeutics</i> , 2020 , 107, 1209-1220	6.1	6
114	Prediction of dolutegravir pharmacokinetics and dose optimization in neonates via physiologically based pharmacokinetic (PBPK) modelling. <i>Journal of Antimicrobial Chemotherapy</i> , 2020 , 75, 640-647	5.1	8
113	Influence of selected polymorphisms in disposition genes on lumefantrine pharmacokinetics when coadministered with efavirenz. <i>Pharmacogenetics and Genomics</i> , 2020 , 30, 96-106	1.9	1
112	The Current Landscape of Novel Formulations and the Role of Mathematical Modeling in Their Development. <i>Journal of Clinical Pharmacology</i> , 2020 , 60 Suppl 1, S77-S97	2.9	3
111	Drug interactions: a review of the unseen danger of experimental COVID-19 therapies. <i>Journal of Antimicrobial Chemotherapy</i> , 2020 , 75, 3417-3424	5.1	16
110	Physiologically Based Pharmacokinetic Modelling to Identify Pharmacokinetic Parameters Driving Drug Exposure Changes in the Elderly. <i>Clinical Pharmacokinetics</i> , 2020 , 59, 383-401	6.2	15

109	Using mechanistic physiologically-based pharmacokinetic models to assess prenatal drug exposure: Thalidomide versus efavirenz as case studies. <i>European Journal of Pharmaceutical Sciences</i> , 2019 , 140, 105068	5.1	10
108	Semi-solid prodrug nanoparticles for long-acting delivery of water-soluble antiretroviral drugs within combination HIV therapies. <i>Nature Communications</i> , 2019 , 10, 1413	17.4	19
107	Improving maraviroc oral bioavailability by formation of solid drug nanoparticles. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2019 , 138, 30-36	5.7	16
106	Effect of patient genetics on etonogestrel pharmacokinetics when combined with efavirenz or nevirapine ART. <i>Journal of Antimicrobial Chemotherapy</i> , 2019 , 74, 3003-3010	5.1	5
105	Modelling the intradermal delivery of microneedle array patches for long-acting antiretrovirals using PBPK. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2019 , 144, 101-109	5.7	18
104	Impact of pharmacogenetics and pregnancy on tenofovir and emtricitabine pharmacokinetics. <i>Pharmacogenomics</i> , 2019 , 20, 217-223	2.6	1
103	A comprehensive framework for physiologically based pharmacokinetic modelling in Matlab. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2019 , 8, 444	4.5	14
102	Anhydrous nanoprecipitation for the preparation of nanodispersions of tenofovir disoproxil fumarate in oils as candidate long-acting injectable depot formulations. <i>Nanoscale Advances</i> , 2019 , 1, 4301-4307	5.1	4
101	Repository Describing an Aging Population to Inform Physiologically Based Pharmacokinetic Models Considering Anatomical, Physiological, and Biological Age-Dependent Changes. <i>Clinical Pharmacokinetics</i> , 2019 , 58, 483-501	6.2	31
100	Predicting Drug-Drug Interactions Between Rifampicin and Long-Acting Cabotegravir and Rilpivirine Using Physiologically Based Pharmacokinetic Modeling. <i>Journal of Infectious Diseases</i> , 2019 , 219, 1735-1742	7	26
99	Towards a Maraviroc long-acting injectable nanoformulation. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2019 , 138, 92-98	5.7	17
98	Mechanisms of Drug Interactions II: Transport Proteins 2018 , 49-85		2
97	Analysis of Clinical Drug-Drug Interaction Data To Predict Magnitudes of Uncharacterized Interactions between Antiretroviral Drugs and Comedications. <i>Antimicrobial Agents and Chemotherapy</i> , 2018 , 62,	5.9	11
96	Derivation of CYP3A4 and CYP2B6 degradation rate constants in primary human hepatocytes: A siRNA-silencing-based approach. <i>Drug Metabolism and Pharmacokinetics</i> , 2018 , 33, 179-187	2.2	8
95	Physiologically based pharmacokinetic modelling prediction of the effects of dose adjustment in drug-drug interactions between levonorgestrel contraceptive implants and efavirenz-based ART. <i>Journal of Antimicrobial Chemotherapy</i> , 2018 , 73, 1004-1012	5.1	12
94	Development, validation and utilization of a highly sensitive LC-MS/MS method for quantification of levonorgestrel released from a subdermal implant in human plasma. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2018 , 1084, 106-112	3.2	7
93	In Silico Dose Prediction for Long-Acting Rilpivirine and Cabotegravir Administration to Children and Adolescents. <i>Clinical Pharmacokinetics</i> , 2018 , 57, 255-266	6.2	19
92	Effect of Pregnancy on the Pharmacokinetic Interaction between Efavirenz and Lumefantrine in HIV-Malaria Coinfection. <i>Antimicrobial Agents and Chemotherapy</i> , 2018 , 62,	5.9	7

91	Prediction and optimization of photo-activated curcumin dosage schedule in human, a promising antimicrobial candidate: A physiologically-based pharmacokinetic (PBPK) modeling. <i>Proceedings for Annual Meeting of the Japanese Pharmacological Society</i> , 2018 , WCP2018, PO1-11-30	0	
90	Development of Prodrug Approaches for Long-Acting Nanoformulations of Emtricitabine-Based Regimens. <i>FASEB Journal</i> , 2018 , 32, 828.3	0.9	
89	Inhibitory Effects of Commonly Used Excipients on P-Glycoprotein in Vitro. <i>Molecular Pharmaceutics</i> , 2018 , 15, 4835-4842	5.6	29
88	The emerging role of physiologically based pharmacokinetic modelling in solid drug nanoparticle translation. <i>Advanced Drug Delivery Reviews</i> , 2018 , 131, 116-121	18.5	4
87	Interaction of Rifampin and Darunavir-Ritonavir or Darunavir-Cobicistat. <i>Antimicrobial Agents and Chemotherapy</i> , 2017 , 61,	5.9	10
86	A physiologically based pharmacokinetic model to predict the superparamagnetic iron oxide nanoparticles (SPIONs) accumulation in vivo. <i>European Journal of Nanomedicine</i> , 2017 , 9,		4
85	Integrated pharmacokinetic modelling for accelerated nanomedicine translation. <i>European Journal of Nanomedicine</i> , 2017 , 9, 1-3		1
84	Dual-stimuli responsive injectable microgel/solid drug nanoparticle nanocomposites for release of poorly soluble drugs. <i>Nanoscale</i> , 2017 , 9, 6302-6314	7.7	28
83	Incompatibility of chemical protein synthesis inhibitors with accurate measurement of extended protein degradation rates. <i>Pharmacology Research and Perspectives</i> , 2017 , 5, e00359	3.1	7
82	Simulating Intestinal Transporter and Enzyme Activity in a Physiologically Based Pharmacokinetic Model for Tenofovir Disoproxil Fumarate. <i>Antimicrobial Agents and Chemotherapy</i> , 2017 , 61,	5.9	5
81	In vitro characterisation of solid drug nanoparticle compositions of efavirenz in a brain endothelium cell line. <i>Journal of Interdisciplinary Nanomedicine</i> , 2017 , 2, 157-169	4	
80	Efavirenz Is Predicted To Accumulate in Brain Tissue: an In Silico, In Vitro, and In Vivo Investigation. <i>Antimicrobial Agents and Chemotherapy</i> , 2017 , 61,	5.9	15
79	Physiologically Based Pharmacokinetic Modeling to Predict Drug-Drug Interactions with Efavirenz Involving Simultaneous Inducing and Inhibitory Effects on Cytochromes. <i>Clinical Pharmacokinetics</i> , 2017 , 56, 409-420	6.2	15
78	Use of a physiologically based pharmacokinetic model to simulate drug-drug interactions between antineoplastic and antiretroviral drugs. <i>Journal of Antimicrobial Chemotherapy</i> , 2017 , 72, 805-811	5.1	11
77	Towards a rational design of solid drug nanoparticles with optimised pharmacological properties. <i>Journal of Interdisciplinary Nanomedicine</i> , 2016 , 1, 110-123	4	13
76	Accelerated oral nanomedicine discovery from miniaturized screening to clinical production exemplified by paediatric HIV nanotherapies. <i>Nature Communications</i> , 2016 , 7, 13184	17.4	35
75	Simulation of the impact of rifampicin on once-daily darunavir/ritonavir pharmacokinetics and dose adjustment strategies: a population pharmacokinetic approach. <i>Journal of Antimicrobial Chemotherapy</i> , 2016 , 71, 1041-5	5.1	4
74	Towards a computational prediction of nanoparticle pharmacokinetics and distribution 2016 , 02,		4

73	Computational Predictive Models for Nanomedicine 2016 , 379-402		
72	Validation of Computational Approaches for Antiretroviral Dose Optimization. <i>Antimicrobial Agents and Chemotherapy</i> , 2016 , 60, 3838-9	5.9	2
71	Development and validation of an LC-MS/MS assay for the quantification of efavirenz in different biological matrices. <i>Bioanalysis</i> , 2016 , 8, 2125-34	2.1	1
70	Interactions of antiretroviral drugs with the SLC22A1 (OCT1) drug transporter. <i>Frontiers in Pharmacology</i> , 2015 , 6, 78	5.6	17
69	Validation and clinical application of a method to quantify nevirapine in dried blood spots and dried breast-milk spots. <i>Journal of Antimicrobial Chemotherapy</i> , 2015 , 70, 2816-22	5.1	15
68	Breast milk pharmacokinetics of efavirenz and breastfed infants exposure in genetically defined subgroups of mother-infant pairs: an observational study. <i>Clinical Infectious Diseases</i> , 2015 , 61, 453-63	11.6	25
67	Applications of physiologically based pharmacokinetic modeling for the optimization of anti-infective therapies. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2015 , 11, 1203-17	5.5	11
66	Impact of body weight on virological and immunological responses to efavirenz-containing regimens in HIV-infected, treatment-naive adults. <i>Aids</i> , 2015 , 29, 193-200	3.5	9
65	Development, validation and clinical application of a novel method for the quantification of efavirenz in dried breast milk spots using LC-MS/MS. <i>Journal of Antimicrobial Chemotherapy</i> , 2015 , 70, 555-61	5.1	28
64	Class-specific relative genetic contribution for key antiretroviral drugs. <i>Journal of Antimicrobial Chemotherapy</i> , 2015 , 70, 3074-9	5.1	10
63	Misoprostol-induced fever and genetic polymorphisms in drug transporters SLCO1B1 and ABCC4 in women of Latin American and European ancestry. <i>Pharmacogenomics</i> , 2015 , 16, 919-28	2.6	10
62	Augmented Inhibition of CYP3A4 in Human Primary Hepatocytes by Ritonavir Solid Drug Nanoparticles. <i>Molecular Pharmaceutics</i> , 2015 , 12, 3556-68	5.6	14
61	Physiologically Based Pharmacokinetic Modelling to Inform Development of Intramuscular Long-Acting Nanoformulations for HIV. <i>Clinical Pharmacokinetics</i> , 2015 , 54, 639-50	6.2	57
60	Flow cytometric analysis of the physical and protein-binding characteristics of solid drug nanoparticle suspensions. <i>Nanomedicine</i> , 2015 , 10, 1407-21	5.6	8
59	The Application of Nanotechnology to Drug Delivery in Medicine 2015 , 173-223		11
58	Use of in vitro to in vivo extrapolation to predict the optimal strategy for patients switching from efavirenz to maraviroc or nevirapine. <i>Clinical Pharmacokinetics</i> , 2015 , 54, 107-16	6.2	2
57	Optimizing nanomedicine pharmacokinetics using physiologically based pharmacokinetics modelling. <i>British Journal of Pharmacology</i> , 2014 , 171, 3963-79	8.6	67
56	Simulation of the impact of rifampicin on darunavir/ritonavir PK and dose adjustment strategies in HIV-infected patients: a population PK approach. <i>Journal of the International AIDS Society</i> , 2014 , 17, 195864	5.4	3

55	CYP2B6 516G>T (rs3745274) and smoking status are associated with efavirenz plasma concentration in a Serbian cohort of HIV patients. <i>Therapeutic Drug Monitoring</i> , 2014 , 36, 734-8	3.2	10
54	CYP3A4*22 (c.522-191 C>T; rs35599367) is associated with lopinavir pharmacokinetics in HIV-positive adults. <i>Pharmacogenetics and Genomics</i> , 2014 , 24, 459-63	1.9	21
53	A multisystem investigation of raltegravir association with intestinal tissue: implications for pre-exposure prophylaxis and eradication. <i>Journal of Antimicrobial Chemotherapy</i> , 2014 , 69, 3275-81	5.1	2
52	Antiretroviral solid drug nanoparticles with enhanced oral bioavailability: production, characterization, and in vitro-in vivo correlation. <i>Advanced Healthcare Materials</i> , 2014 , 3, 400-11	10.1	62
51	Use of a physiologically-based pharmacokinetic model to simulate artemether dose adjustment for overcoming the drug-drug interaction with efavirenz. <i>In Silico Pharmacology</i> , 2013 , 1, 4	4.3	24
50	Prediction of drug-drug interactions between various antidepressants and efavirenz or boosted protease inhibitors using a physiologically based pharmacokinetic modelling approach. <i>Clinical Pharmacokinetics</i> , 2013 , 52, 583-92	6.2	43
49	Correlates of efavirenz exposure in Chilean patients affected with human immunodeficiency virus reveals a novel association with a polymorphism in the constitutive androstane receptor. <i>Therapeutic Drug Monitoring</i> , 2013 , 35, 78-83	3.2	32
48	Intracellular accumulation of ritonavir combined with different protease inhibitors and correlations between concentrations in plasma and peripheral blood mononuclear cells. <i>Journal of Antimicrobial Chemotherapy</i> , 2013 , 68, 907-10	5.1	18
47	Predicting intestinal absorption of raltegravir using a population-based ADME simulation. <i>Journal of Antimicrobial Chemotherapy</i> , 2013 , 68, 1627-34	5.1	19
46	Rilpivirine inhibits drug transporters ABCB1, SLC22A1, and SLC22A2 in vitro. <i>Antimicrobial Agents and Chemotherapy</i> , 2013 , 57, 5612-8	5.9	23
45	Nanomedicines for HIV therapy. <i>Therapeutic Delivery</i> , 2013 , 4, 153-6	3.8	19
44	Physiologically based pharmacokinetic models for the optimization of antiretroviral therapy: recent progress and future perspective. <i>Future Virology</i> , 2013 , 8, 871-890	2.4	8
43	Influence of CYP2B6 and ABCB1 SNPs on nevirapine plasma concentrations in Burundese HIV-positive patients using dried sample spot devices. <i>British Journal of Clinical Pharmacology</i> , 2012 , 74, 134-40	3.8	29
42	Divalent metals and pH alter raltegravir disposition in vitro. <i>Antimicrobial Agents and Chemotherapy</i> , 2012 , 56, 3020-6	5.9	46
41	Once daily maraviroc 300 mg or 150 mg in combination with ritonavir-boosted darunavir 800/100 mg. <i>Journal of Antimicrobial Chemotherapy</i> , 2012 , 67, 671-4	5.1	22
40	Inpatient and interpatient pharmacokinetic variability of raltegravir in the clinical setting. <i>Therapeutic Drug Monitoring</i> , 2012 , 34, 232-5	3.2	29
39	Prophylactic drug monitoring of itraconazole in an oncohematological pediatric patient population. <i>Therapeutic Drug Monitoring</i> , 2012 , 34, 604-6	3.2	5
38	Negative predictive value of IL28B, SLC28A2, and CYP27B1 SNPs and low RBV plasma exposure for therapeutic response to PEG/IFN-RBV treatment. <i>Therapeutic Drug Monitoring</i> , 2012 , 34, 722-8	3.2	30

37	Pharmacokinetics of lamivudine and lamivudine-triphosphate after administration of 300 milligrams and 150 milligrams once daily to healthy volunteers: results of the ENCORE 2 study. <i>Antimicrobial Agents and Chemotherapy</i> , 2012 , 56, 1427-33	5.9	25
36	Inosine triphosphatase polymorphisms and ribavirin pharmacokinetics as determinants of ribavirin-associated anemia in patients receiving standard anti-HCV treatment. <i>Therapeutic Drug Monitoring</i> , 2012 , 34, 165-70	3.2	37
35	Association of ABCC10 polymorphisms with nevirapine plasma concentrations in the German Competence Network for HIV/AIDS. <i>Pharmacogenetics and Genomics</i> , 2012 , 22, 10-9	1.9	35
34	Efavirenz in an obese HIV-infected patient--a report and an in vitro-in vivo extrapolation model indicate risk of underdosing. <i>Antiviral Therapy</i> , 2012 , 17, 1381-4	1.6	13
33	Determinants of darunavir cerebrospinal fluid concentrations: impact of once-daily dosing and pharmacogenetics. <i>Aids</i> , 2012 , 26, 1529-33	3.5	33
32	Ceftriaxone bone penetration in patients with septic non-union of the tibia. <i>International Journal of Infectious Diseases</i> , 2011 , 15, e415-21	10.5	18
31	Pharmacokinetics of switching unboosted atazanavir coadministered with tenofovir disoproxil fumarate from 400 mg once daily to 200 mg twice daily in HIV-positive patients. <i>Antiviral Therapy</i> , 2011 , 16, 499-504	1.6	9
30	Ribavirin pharmacokinetics and interleukin 28B plus cytochrome P450 27B1 single-nucleotide polymorphisms as predictors of response to pegylated interferon/ribavirin treatment in patients infected with hepatitis C virus genotype 1/4. <i>Hepatology</i> , 2011 , 54, 2278-9	11.2	25
29	Cytochrome P450 2B6 (CYP2B6) and constitutive androstane receptor (CAR) polymorphisms are associated with early discontinuation of efavirenz-containing regimens. <i>Journal of Antimicrobial Chemotherapy</i> , 2011 , 66, 2092-8	5.1	87
28	A HPLC-MS method for the simultaneous quantification of fourteen antiretroviral agents in peripheral blood mononuclear cell of HIV infected patients optimized using medium corpuscular volume evaluation. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2011 , 54, 779-88	3.5	55
27	Integration of population pharmacokinetics and pharmacogenetics: an aid to optimal nevirapine dose selection in HIV-infected individuals. <i>Journal of Antimicrobial Chemotherapy</i> , 2011 , 66, 1332-9	5.1	42
26	Evaluation of the mean corpuscular volume of peripheral blood mononuclear cells of HIV patients by a coulter counter to determine intracellular drug concentrations. <i>Antimicrobial Agents and Chemotherapy</i> , 2011 , 55, 2976-8	5.9	53
25	Raltegravir is a substrate for SLC22A6: a putative mechanism for the interaction between raltegravir and tenofovir. <i>Antimicrobial Agents and Chemotherapy</i> , 2011 , 55, 879-87	5.9	51
24	Maraviroc is a substrate for OATP1B1 in vitro and maraviroc plasma concentrations are influenced by SLCO1B1 521 T>C polymorphism. <i>Pharmacogenetics and Genomics</i> , 2010 , 20, 759-65	1.9	38
23	Raltegravir penetration in seminal plasma of healthy volunteers. <i>Antimicrobial Agents and Chemotherapy</i> , 2010 , 54, 2744-5	5.9	13
22	Population pharmacokinetic modeling of the association between 63396C->T pregnane X receptor polymorphism and unboosted atazanavir clearance. <i>Antimicrobial Agents and Chemotherapy</i> , 2010 , 54, 5242-50	5.9	63
21	Development, validation, and routine application of a high-performance liquid chromatography method coupled with a single mass detector for quantification of itraconazole, voriconazole, and posaconazole in human plasma. <i>Antimicrobial Agents and Chemotherapy</i> , 2010 , 54, 3408-13	5.9	45
20	A validated high-performance liquid chromatography-ultraviolet method for quantification of the CCR5 inhibitor maraviroc in plasma of HIV-infected patients. <i>Therapeutic Drug Monitoring</i> , 2010 , 32, 86-92	3.2	19

19	Impairment in kidney tubular function in patients receiving tenofovir is associated with higher tenofovir plasma concentrations. <i>Aids</i> , 2010 , 24, 1064-6	3.5	103
18	Development and validation of a simultaneous extraction procedure for HPLC-MS quantification of daptomycin, amikacin, gentamicin, and rifampicin in human plasma. <i>Analytical and Bioanalytical Chemistry</i> , 2010 , 396, 791-8	4.4	64
17	Validation of a rapid and sensitive high-performance liquid chromatography-tandem mass spectrometry (HPLC-MS/MS) assay for the simultaneous determination of existing and new antiretroviral compounds. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2010 , 878, 1455-65	3.2	100
16	HPLC-MS method for the quantification of nine anti-HIV drugs from dry plasma spot on glass filter and their long term stability in different conditions. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2010 , 52, 774-80	3.5	62
15	Lack of interaction between raltegravir and cyclosporin in an HIV-infected liver transplant recipient. <i>Journal of Antimicrobial Chemotherapy</i> , 2009 , 64, 874-5	5.1	9
14	New HPLC-MS method for the simultaneous quantification of the antileukemia drugs imatinib, dasatinib, and nilotinib in human plasma. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2009 , 877, 1721-6	3.2	82
13	Simultaneous quantification of linezolid, rifampicin, levofloxacin, and moxifloxacin in human plasma using high-performance liquid chromatography with UV. <i>Therapeutic Drug Monitoring</i> , 2009 , 31, 104-9	3.2	36
12	Glycopeptide bone penetration in patients with septic pseudoarthrosis of the tibia. <i>Clinical Pharmacokinetics</i> , 2008 , 47, 793-805	6.2	31
11	A new assay based on solid-phase extraction procedure with LC-MS to measure plasmatic concentrations of tenofovir and emtricitabine in HIV infected patients. <i>Journal of Chromatographic Science</i> , 2008 , 46, 524-8	1.4	36
10	Tipranavir (TPV) genotypic inhibitory quotient predicts virological response at 48 weeks to TPV-based salvage regimens. <i>Antimicrobial Agents and Chemotherapy</i> , 2008 , 52, 1066-71	5.9	15
9	Association of a single-nucleotide polymorphism in the pregnane X receptor (PXR 63396C-->T) with reduced concentrations of unboosted atazanavir. <i>Clinical Infectious Diseases</i> , 2008 , 47, 1222-5	11.6	73
8	A simple and fast method for quantification of ertapenem using meropenem as internal standard in human plasma in a clinical setting. <i>Therapeutic Drug Monitoring</i> , 2008 , 30, 90-4	3.2	9
7	An HPLC-PDA method for the simultaneous quantification of the HIV integrase inhibitor raltegravir, the new nonnucleoside reverse transcriptase inhibitor etravirine, and 11 other antiretroviral agents in the plasma of HIV-infected patients. <i>Therapeutic Drug Monitoring</i> , 2008 , 30, 662-9	3.2	99
6	A simple and sensitive assay for determining plasma tipranavir concentration in the clinical setting by new HPLC method. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2007 , 848, 374-8	3.2	22
5	HPLC-MS method for the simultaneous quantification of the new HIV protease inhibitor darunavir, and 11 other antiretroviral agents in plasma of HIV-infected patients. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2007 , 859, 234-40	3.2	77
4	Clinically significant drug interaction between tipranavir-ritonavir and phenobarbital in an HIV-infected subject. <i>Clinical Infectious Diseases</i> , 2007 , 45, 1654-5	11.6	9
3	Unexpected drug-drug interaction between tipranavir/ritonavir and enfuvirtide. <i>Aids</i> , 2006 , 20, 1977-9	3.5	23
2	Validation of liquid/liquid extraction method coupled with HPLC-UV for measurement of ribavirin plasma levels in HCV-positive patients. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2006 , 835, 127-30	3.2	46

- 1 Physiologically-based pharmacokinetic modelling of infant exposure to efavirenz through breastfeeding. *AAS Open Research*,1, 16 1.8 7